TIBER CREEK GROUP for ASTRAZENECA
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicaid Drug Rebates. Reforms to Medicare Part D. CMS guidance on coverage gap in Medicare Part D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| SHEILA MURPHY | — |
| SEAN RICHARDSON | — |
Health Issues HCR
Medicaid Drug Rebates. Reforms to Medicare Part D. S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program. H.R.4213, American Jobs and Closing Tax Loopholes Act of 2010: AMP provision; 340b provisions. H.R.4899, Supplemental Appropriations Act of 2010: Patent Settlement provisions; 340b provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| SHEILA MURPHY | — |
| SEAN RICHARDSON | — |
Pharmacy PHA
S. 525, Pharmaceutical Market Access and Drug Safety Act of 2009. Support for H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program. S.369, Preserve Access to Affordable Generics Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| SHEILA MURPHY | — |
| SEAN RICHARDSON | — |
Medical/Disease Research/Clinical Labs MED
Support for H.R. 1548, Pathway for Biologics Act. H.R. 2502, Comparative Effectiveness Research Act of 2009. Changes to the 340b program.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| SHEILA MURPHY | — |
| SEAN RICHARDSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.